Medicare beneficiaries may soon have a much more affordable path to GLP-1 medications. Starting July 1, 2026, eligible enrollees can access drugs like Wegovy and Zepbound for a flat $50 monthly copay through a new pilot initiative called the Medicare GLP-1 Bridge program. According to a release by the Center for Medicare and Medicade Services, the program runs through December 31, 2027, and is designed to bridge the gap while a longer-term coverage plan is worked out.
To qualify, you must be enrolled in a Medicare Part D plan and meet certain health criteria, either a BMI of 27 or higher with a comorbidity like heart disease or prediabetes, or a BMI of 35 or higher regardless of other conditions.
Eligible medications include injectable and pill forms of Wegovy, and the KwikPen form of Zepbound along with Foundayo, the latest GLP-1 pill to be approved. Notably, doctors don’t need to be enrolled as Medicare providers to write a prescription under this program.
The savings are significant given that current cash prices for GLP-1 medications typically run anywhere from $149 to $699 per month even with discounts. The Bridge program’s $50 copay stays flat regardless of dosage, which is important because the average user will need higher doses if they’ve already been taking the medication or are in maintenance mode.
There are a few trade-offs to report. For one, the copay doesn’t count toward the standard Part D deductible or annual out-of-pocket cap. Also those on the low-income Medicare Extra Help subsidy won’t be able to apply that assistance to Bridge program prescriptions.
What happens after 2027 is still uncertain. The program was initially designed to run for six months, but after too few insurance companies agreed to participate in a voluntary extension, the government stepped in and expanded it to 18 months. This gives everyone more time to negotiate a permanent solution, but the costs are no joke—experts estimate it could end up costing Medicare billions of dollars every year based on how many people use it.
